In a report released yesterday, from Oppenheimer assigned a Hold rating to Resmed. The company’s shares closed yesterday at $211.94.Claim 55% O...
In addition to Oppenheimer, Resmed also received a Hold from Needham’s Michael Matson in a report issued yesterday. However, on the same day, KeyBanc maintained a Buy rating on Resmed (NYSE: RMD).
Based on Resmed’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.46 billion and a net profit of $383.43 million. In comparison, last year the company earned a revenue of $1.35 billion and had a net profit of $379.71 million
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Siemens Healthineers AG…
Macquarie analyst maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh today and…
ResMed is selling MatrixCare for $490 million to sharpen its sleep health focus as analysts weigh near-term EPS dilution against…
Ord Minnett analyst maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh today and…
UBS analyst David Low maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh…
In a report released today, Derek Jellinek from Morgans maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a…
